On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") announced the top-line results of its SYCAMORE trial, a Phase 2 study for REC-994 in symptomatic cerebral cavernous malformation (CCM) patients. The trial met its primary endpoint of safety and tolerability and showed encouraging trends in MRI-based exploratory efficacy measures at the highest dose. Recursion plans to advance the development of REC-994 for CCM treatment and intends to discuss further clinical studies with the FDA. Additionally, Recursion has entered into a transaction agreement with Exscientia plc ("Exscientia"), which, subject to conditions including stockholder approvals, will result in Recursion acquiring Exscientia. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts anticipated over the next 18 months. The transaction is projected to close by early 2025, with Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined entity. The merger aims to leverage technology to discover and develop high-quality medicines efficiently and at scale.

On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") announced the top-line results of its SYCAMORE trial, a Phase 2 study for REC-994 in symptomatic cerebral cavernous malformation (CCM) patients. The trial met its primary endpoint of safety and tolerability and showed encouraging trends in MRI-based exploratory efficacy measures at the highest dose. Recursion plans to advance the development of REC-994 for CCM treatment and intends to discuss further clinical studies with the FDA. Additionally, Recursion has entered into a transaction agreement with Exscientia plc ("Exscientia"), which, subject to conditions including stockholder approvals, will result in Recursion acquiring Exscientia. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts anticipated over the next 18 months. The transaction is projected to close by early 2025, with Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined entity. The merger aims to leverage technology to discover and develop high-quality medicines efficiently and at scale.